Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Recruiting
N/A
Interventional Study
Aging
Frailty
Exercise Tolerance
Healthy Male and Female Subjects
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 60 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 40 (estimated)
- Sponsor
- Scott Silveira · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults.
The primary outcome is cycle ergome…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults aged 60 to 80 years, of any sex
* Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study
* Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated …
Contacts
No contact information available.